Latest / AI Investment Edge: Stocks, Markets & Money / Novo Nordisk: Huge Demand, Harder Profits | EP024
Transcript
- 0:00SPEAKER_00: Okay, let's unpack this.
- 0:02SPEAKER_00: I mean, imagine you are running a massive blockbuster movie studio, right?
- 0:07SPEAKER_00: They've just released the single most popular film in the entire world.
- 0:10SPEAKER_01: Huge lines.
- 0:10SPEAKER_00: Yeah, everyone wants to see it.
- 0:12SPEAKER_00: Exactly.
- 0:12SPEAKER_00: Lines wrapping around the block in every city.
- 0:15SPEAKER_00: But there's a massive catch.
- 0:17SPEAKER_00: To keep the audience coming,
- 0:18SPEAKER_00: you suddenly have to build your own incredibly expensive movie theaters
- 0:22SPEAKER_00: from scratch.
- 0:23SPEAKER_01: Right.
- 0:23SPEAKER_01: Right.
- 0:24SPEAKER_00: And while you're pouring concrete and buying projectors,
- 0:26SPEAKER_00: you are being pressured by regulators and competitors to lower the price
- 0:30SPEAKER_00: of your tickets.
- 0:31SPEAKER_01: It's a brutal dynamic.
- 0:32SPEAKER_00: It is.
- 0:33SPEAKER_00: So you have this unprecedented historical demand,
- 0:35SPEAKER_00: but your costs to physically serve that demand are just skyrocketing
- 0:39SPEAKER_00: while your per ticket revenue shrinks.
- 0:41SPEAKER_00: We are looking at the AI investment edge from iPulse AI today
- 0:45SPEAKER_00: to answer one core mission for you.
- 0:47SPEAKER_00: How does a company translate that kind of massive patient demand into durable,
- 0:51SPEAKER_00: profitable earnings without destroying its margins in the process?
- 0:54SPEAKER_01: Yeah.
- 0:55SPEAKER_01: And that tension between top line volume and bottom line reality is
- 1:00SPEAKER_01: the defining question for Novo Nordisk right now.
- 1:03SPEAKER_01: I mean, patients clearly want the medicines.
- 1:05SPEAKER_00: Right.
- 1:05SPEAKER_00: The demand is obvious.
- 1:06SPEAKER_01: But the actual value of a business isn't just about how many people want the product.
- 1:10SPEAKER_01: The critical puzzle
- 1:11SPEAKER_01: for anyone analyzing this stock is determining how much actual economic growth NOVA
- 1:15SPEAKER_01: retains after clearing all these hurdles.
- 1:19SPEAKER_00: The pricing pressure, the research.
- 1:21SPEAKER_01: Exactly.
- 1:21SPEAKER_01: Intense pricing pressure,
- 1:23SPEAKER_01: relentless clinical research,
- 1:25SPEAKER_01: and multi-billion dollar capital investments into new manufacturing facilities.
- 1:29SPEAKER_00: And we are talking about a Danish pharmaceutical giant here.
- 1:32SPEAKER_00: You're almost certainly familiar with their portfolio,
- 1:35SPEAKER_00: their major diabetes, obesity, and rare disease medicines.
- 1:38SPEAKER_00: We're looking at the massive franchises of Ozempic,
- 1:41SPEAKER_00: Wegovi, and their established insulin products.
- 1:43SPEAKER_01: The big ones.
- 1:44SPEAKER_00: Yeah.
- 1:45SPEAKER_00: And just to lock in the reality of this timeline for everyone listening,
- 1:49SPEAKER_00: Oral Wegovi actually launched in the U.S. back on January 5th, 2026.
- 1:53SPEAKER_00: This isn't some distant catalyst sitting in a pipeline somewhere.
- 1:57SPEAKER_01: No, it's already out there.
- 1:58SPEAKER_01: Existing side by side with the injectable options.
- 2:01SPEAKER_01: And because those products are already in the market, the narrative has fundamentally shifted.
- 2:06SPEAKER_00: How so?
- 2:07SPEAKER_01: Well, we've moved past the initial hype phase of,
- 2:10SPEAKER_01: you know, will people take these weight loss and diabetes drugs?
- 2:12SPEAKER_00: Right.
- 2:12SPEAKER_00: The market knows they will.
- 2:14SPEAKER_01: Exactly.
- 2:15SPEAKER_01: The analysis now demands a look at the hard,
- 2:18SPEAKER_01: unglamorous numbers to see if the company is actually overcoming the friction
- 2:22SPEAKER_01: of scale.
- 2:23SPEAKER_01: We are looking for proof that they can handle this safely and profitably.
- 2:27SPEAKER_00: So let's crack open those numbers because reading
- 2:30SPEAKER_00: the headline revenue can be incredibly misleading here.
- 2:33SPEAKER_01: Very.
- 2:34SPEAKER_00: If we look at the half year ended June 30, 2026,
- 2:37SPEAKER_00: the reported sales were a staggering 175.3 billion Danish kroner,
- 2:43SPEAKER_00: but the adjusted sales were only 148.6 billion.
- 2:47SPEAKER_01: That is a massive gap.
- 2:49SPEAKER_00: It's huge, right?
- 2:50SPEAKER_00: So the headline surge is basically an accounting picture.
- 2:53SPEAKER_00: It's like finding a $20 bill in an old coat and counting it as your weekly salary.
- 2:57SPEAKER_00: It doesn't actually mean you got a raise.
- 2:59SPEAKER_01: That is a perfect analogy.
- 3:02SPEAKER_01: The discrepancy comes down to a very specific accounting event in the first quarter.
- 3:06SPEAKER_01: It was a 26.8 billion kroner reversal regarding a U.S. 340B sales rebate provision.
- 3:12SPEAKER_00: Okay, break that down for us.
- 3:13SPEAKER_00: What is a rebate provision?
- 3:15SPEAKER_01: So you have to realize that a rebate provision is essentially
- 3:19SPEAKER_01: a mental rainy day fund a company creates.
- 3:22SPEAKER_01: They estimate they'll owe certain government discounts,
- 3:24SPEAKER_01: so they hold that value back on their books.
- 3:26SPEAKER_00: Like setting aside money for taxes.
- 3:28SPEAKER_01: Right.
- 3:29SPEAKER_01: When they remeasure that estimate and realize they don't owe as much
- 3:33SPEAKER_01: as they thought, they release it back onto the income statement.
- 3:37SPEAKER_01: It instantly inflates the reported revenue and profits.
- 3:41SPEAKER_01: But, this is the crucial part, that reversal had zero cash impact.
- 3:46SPEAKER_01: No new cash actually entered the bank account.
- 3:49SPEAKER_00: So if you just skim the press release,
- 3:50SPEAKER_00: you see this massive 1.75 billion kroner figure and assume they sold
- 3:55SPEAKER_00: that much more medicine.
- 3:56SPEAKER_01: Which they didn't.
- 3:57SPEAKER_00: Right.
- 3:58SPEAKER_00: When you strip away that one-time accounting release, you see the actual underlying business.
- 4:02SPEAKER_00: And those adjusted sales only grew 2% at constant exchange rates.
- 4:06SPEAKER_00: That really changes the temperature of the growth story.
- 4:09SPEAKER_01: It really does.
- 4:10SPEAKER_01: And, you know, the accounting adjustments don't stop there.
- 4:14SPEAKER_01: In the second quarter, they recorded 6.3 billion krona in non-cash pipeline impairments.
- 4:19SPEAKER_00: Wow.
- 4:20SPEAKER_00: Where did that come from?
- 4:21SPEAKER_01: Well, 4.0 billion of that came just from Mon Lunabont.
- 4:26SPEAKER_01: An impairment means the company looked at an asset they were developing,
- 4:30SPEAKER_01: realized its future economic value is significantly lower
- 4:33SPEAKER_01: than they originally modeled, and took a write down.
- 4:36SPEAKER_00: So again, no cash actually left the building today.
- 4:38SPEAKER_01: Correct.
- 4:39SPEAKER_01: But it is a direct hit to the long term investment record of their research and development.
- 4:44SPEAKER_01: So to find the true adjusted operating margin of 44.6%,
- 4:49SPEAKER_01: you have to back out that massive positive rebate reversal
- 4:53SPEAKER_01: and add back those impairment charges.
- 4:55SPEAKER_00: Because those underlying costs are so high and the net price is under pressure,
- 4:59SPEAKER_00: we really have to scrutinize what's actually surviving to the bottom line.
- 5:04SPEAKER_00: And that gross margin story is where the friction is like most obvious.
- 5:08SPEAKER_01: Yeah, it dropped.
- 5:09SPEAKER_00: Right.
- 5:09SPEAKER_00: We went from an adjusted gross margin of 83.1% in the prior first half down to 79.3%
- 5:15SPEAKER_00: in this current first half.
- 5:18SPEAKER_00: That is a meaningful compression for a company operating at this scale.
- 5:22SPEAKER_01: That drop is the numerical manifestation of the headwinds we just discussed.
- 5:27SPEAKER_01: It reflects net price pressure,
- 5:29SPEAKER_01: fierce market competition,
- 5:31SPEAKER_01: the evolving mix of products being sold,
- 5:33SPEAKER_01: and heavily the depreciation costs kicking in
- 5:35SPEAKER_01: from all their manufacturing expansions.
- 5:38SPEAKER_00: And funding that expansion requires significant leverage, right?
- 5:41SPEAKER_01: Absolutely.
- 5:42SPEAKER_01: The balance sheet shows a company-defined net debt of 86.5 billion krona.
- 5:47SPEAKER_00: Okay.
- 5:48SPEAKER_01: And that figure already subtracts the 44.5 billion they have sitting in cash at
- 5:52SPEAKER_01: the bank, meaning the remaining financing burden is still substantial.
- 5:56SPEAKER_00: Which shatters any illusion that this is just some mature cash cow business coasting
- 6:02SPEAKER_00: on its patents.
- 6:02SPEAKER_00: I mean, they are building the airplane while flying it.
- 6:05SPEAKER_01: Completely.
- 6:06SPEAKER_00: The first half free cash flow was 55.3 billion kroner,
- 6:10SPEAKER_00: but they are guiding for around 55 billion in property,
- 6:13SPEAKER_00: plant, and equipment spending for the full year alone.
- 6:16SPEAKER_00: They are pouring their cash right back into the ground to build these factories.
- 6:20SPEAKER_01: The capital intensity is relentless.
- 6:22SPEAKER_01: We actually discussed a very similar accounting dynamic in our companion deep dive
- 6:26SPEAKER_01: on Volkswagen, EP018.
- 6:28SPEAKER_00: Oh right, the CapEx stuff.
- 6:30SPEAKER_01: Exactly.
- 6:31SPEAKER_01: You always have to separate the reported headline accounting charges from
- 6:34SPEAKER_01: the underlying operating reality.
- 6:37SPEAKER_01: The capital expenditures dictate the future far more than a one time rebate adjustment.
- 6:41SPEAKER_00: So let's transition from how the company is performing internally to how
- 6:45SPEAKER_00: the market is actually pricing that performance today,
- 6:48SPEAKER_00: because the spread of opinions here is wild.
- 6:51SPEAKER_01: It's all over the place.
- 6:53SPEAKER_00: We are looking at the specific research security for
- 6:55SPEAKER_00: the Novo Nordisk Ordinary B-Share, traded as nov.xetra in euros.
- 7:02SPEAKER_00: The reference price from the October 16, 2026 close is 34.80 euros.
- 7:05SPEAKER_00: Okay.
- 7:09SPEAKER_00: From that starting line,
- 7:10SPEAKER_00: the September weighted base price path models a cumulative appreciation
- 7:14SPEAKER_00: of plus 25.9% by September 18, 2027, and a clean plus 100.0% by September 18, 2031.
- 7:25SPEAKER_01: But before we go further, we must define what a weighted base path actually is in these models.
- 7:31SPEAKER_01: It aggregates various research forecasts using evidence weights.
- 7:35SPEAKER_00: Which means...
- 7:37SPEAKER_01: It is vital to understand that an evidence weight is not a calibrated mathematical probability.
- 7:42SPEAKER_01: It does not mean there is a 100% chance or even a highly probable chance of hitting
- 7:47SPEAKER_01: that exact number.
- 7:48SPEAKER_01: It is simply an aggregation of the analytical conviction at this specific moment in time.
- 7:54SPEAKER_00: So what does this all mean for the dividends?
- 7:56SPEAKER_00: And we need to be careful not to mistake evidence weights for
- 7:59SPEAKER_00: a magical crystal ball probability, right?
- 8:02SPEAKER_01: Right, there are absolutely no probabilities attached here,
- 8:05SPEAKER_01: just like with the alternate scenarios provided in the research.
- 8:08SPEAKER_00: Yeah, the simple averaged bull case implies returns of plus 50.9% for 2027 and
- 8:12SPEAKER_00: a massive plus 154.9% by 2031.
- 8:13SPEAKER_00: But the bear case projects only plus 6.4% for 2027 and plus 39.2% for 2031.
- 8:25SPEAKER_01: Neither of those have assigned probabilities either.
- 8:28SPEAKER_01: But that massive spread between a 39% gain and a 150% gain tells us
- 8:34SPEAKER_01: the market is incredibly divided on
- 8:36SPEAKER_01: whether these multi-billion dollar factory investments will actually pay off.
- 8:40SPEAKER_00: So the market is fundamentally debating the terminal value of the stock.
- 8:44SPEAKER_01: Exactly.
- 8:45SPEAKER_01: But while that debate rages,
- 8:47SPEAKER_01: there is direct numerical accounting for the cash actually returning
- 8:50SPEAKER_01: to investors right now via dividends.
- 8:53SPEAKER_01: Let's walk through the math.
- 8:54SPEAKER_00: Okay, let's do it.
- 8:55SPEAKER_01: Novo paid a final dividend of 7.95 kroner on March 31st,
- 9:00SPEAKER_01: 2026 and an interim dividend of 3.75 kroner on August 18th, 2026.
- 9:08SPEAKER_00: So together that equals 11.70 kroner annually.
- 9:11SPEAKER_01: Right.
- 9:12SPEAKER_01: And if you simply project that flat amount forward over five future cycles
- 9:16SPEAKER_01: to our September 2031 endpoint, you get 58.50 kroner.
- 9:21SPEAKER_00: Now, to make that comparable to our 34.80 euro share price, we have to run the exchange math.
- 9:27SPEAKER_00: Using a fixed illustrative exchange rate from mid-October,
- 9:30SPEAKER_00: where 1 euro equals roughly 7.4748 Danish kroner,
- 9:35SPEAKER_00: that annual cash stream converts to 1.57 euros per share before the 2027 endpoint
- 9:38SPEAKER_00: and 7.83 euros per share before the 2031 endpoint.
- 9:45SPEAKER_01: And if we add those exact cash amounts directly to the weighted terminal prices,
- 9:50SPEAKER_01: we arrive at a cumulative cash-inclusive base return of plus 30.4% for 2027
- 9:57SPEAKER_01: and plus 122.5% for 2031.
- 10:00SPEAKER_00: But we have to be super clear on what that actually means.
- 10:03SPEAKER_01: We must be incredibly disciplined about what that calculation represents.
- 10:07SPEAKER_01: It is purely gross before any taxes or portfolio fees.
- 10:11SPEAKER_01: It assumes absolutely no reinvestment of those dividends over the five years.
- 10:15SPEAKER_00: Right.
- 10:15SPEAKER_00: No compounding.
- 10:16SPEAKER_01: Exactly.
- 10:17SPEAKER_01: Furthermore, there is zero yield rhetoric here.
- 10:20SPEAKER_01: We are not arguing the stock is a good income play.
- 10:24SPEAKER_01: We are just demonstrating the straight arithmetic of adding
- 10:27SPEAKER_01: the generated cash per share to the projected terminal price
- 10:31SPEAKER_01: to understand total possible return.
- 10:34SPEAKER_00: OK, now that we have the math laid out,
- 10:36SPEAKER_00: we need to understand the gears actually turning the machine.
- 10:39SPEAKER_00: The research categorizes the fundamental mechanisms driving the stock into four quadrants.
- 10:44SPEAKER_01: The driver, the friction, the upside tail, and the downside tail.
- 10:49SPEAKER_01: Right.
- 10:50SPEAKER_00: The driver is fairly straightforward.
- 10:51SPEAKER_00: It's the push for broader oral and injectable patient reach and increasing
- 10:56SPEAKER_00: the sheer throughput of their factories.
- 10:58SPEAKER_01: Here's where it comes.
- 11:24SPEAKER_00: I always think of it like getting your driver's license.
- 11:27SPEAKER_00: Having a clinical indication is like getting your driver's license,
- 11:30SPEAKER_00: but payer coverage is finding out if someone else is actually going to pay for
- 11:33SPEAKER_00: the car.
- 11:34SPEAKER_00: They are not the same thing.
- 11:36SPEAKER_00: Getting the FDA's blessing doesn't magically force an insurer to open their checkbook.
- 11:41SPEAKER_01: That's spot on.
- 11:42SPEAKER_01: Approval, reimbursement, and commercial success are distinct steps.
- 11:47SPEAKER_01: And that reality feeds directly into the friction quadrant.
- 11:50SPEAKER_01: Right.
- 11:50SPEAKER_01: To secure that payer coverage,
- 11:52SPEAKER_01: Novo has to accept lower realized prices and offer massive rebates.
- 11:57SPEAKER_01: Add in the fierce competition from Eli Lilly and the heavy depreciation costs
- 12:01SPEAKER_01: from all those new factories,
- 12:03SPEAKER_01: and you see why revenue growth doesn't seamlessly translate into profit growth.
- 12:07SPEAKER_00: So let's clarify the extremes, the tails.
- 12:10SPEAKER_00: The research strictly defines the upside tail as
- 12:13SPEAKER_00: a successful breakthrough successor medicine,
- 12:15SPEAKER_00: like a next generation treatment that massively exceeds both clinical
- 12:19SPEAKER_00: and commercial expectations.
- 12:21SPEAKER_01: And we should be very clear here.
- 12:23SPEAKER_01: The Medicare GLP-1 bridge that began on July 1,
- 12:26SPEAKER_01: 2026 is already baked into the baseline assumptions.
- 12:29SPEAKER_00: It's not the upside.
- 12:31SPEAKER_01: No, it is not an upside tail event.
- 12:33SPEAKER_01: Current payer access is baseline.
- 12:36SPEAKER_01: The market already expects that uptake.
- 12:38SPEAKER_01: An upside tail must be conditionally new.
- 12:41SPEAKER_00: And the downside tail?
- 12:43SPEAKER_01: That represents a structural break in the thesis.
- 12:45SPEAKER_01: This would be strictly an unexpected major safety or regulatory restriction or
- 12:50SPEAKER_01: an adverse patent or generic outcome that suddenly truncates the lifespan
- 12:54SPEAKER_01: of their highly profitable revenues.
- 12:56SPEAKER_00: So all of these forces pushing against each other create what the research calls the alpha gap.
- 13:01SPEAKER_00: It's the tension between the unprecedented patient demand on one side and
- 13:04SPEAKER_00: the sinking net prices and billions in infrastructure costs on the other.
- 13:08SPEAKER_00: It's like a massive scale.
- 13:10SPEAKER_01: Exactly.
- 13:10SPEAKER_00: Does sheer volume automatically equal value for the listener's portfolio?
- 13:15SPEAKER_01: If we connect this to the bigger picture, the historical answer to that is no.
- 13:20SPEAKER_01: Lower product prices do not automatically create shareholder value unless
- 13:24SPEAKER_01: the pure volume of new patients and the manufacturing efficiency of
- 13:27SPEAKER_01: the new factories completely overwhelm the price erosion.
- 13:30SPEAKER_00: Right.
- 13:31SPEAKER_01: Building a state of the art facility only creates value if the commercial returns
- 13:35SPEAKER_01: over the next decade justify the resources you incinerated to build it today.
- 13:39SPEAKER_01: We actually explored a mirror image of this dynamic in our NVIDIA EP 013 companion deep dive.
- 13:45SPEAKER_01: You have world changing, undeniable demand.
- 13:48SPEAKER_01: But you have to weigh it against the sheer mountain of cash required to build
- 13:51SPEAKER_01: the infrastructure to actually serve it.
- 13:53SPEAKER_00: And because that alpha gap is so wide,
- 13:55SPEAKER_00: the underlying AI models analyzing Novo stock are completely fractured
- 13:59SPEAKER_00: in their conclusions.
- 14:00SPEAKER_00: I mean, we are looking at a September batch of 14 different AI research contributions.
- 14:05SPEAKER_00: These utilize nine framework personas and three model versions,
- 14:08SPEAKER_00: with 12 of them sharing a specific Gemini version.
- 14:11SPEAKER_00: It's fascinating because it proves that AI isn't just this monolith.
- 14:15SPEAKER_00: It's like having a room full of brilliant analysts looking at the exact same factory
- 14:19SPEAKER_00: and arguing whether it's a gold mine or an expensive money pit.
- 14:22SPEAKER_01: That's exactly it.
- 14:24SPEAKER_01: Because they are correlated AI perspectives weighing variables differently,
- 14:28SPEAKER_01: not 14 independent human minds.
- 14:31SPEAKER_01: Right.
- 14:31SPEAKER_01: Right.
- 14:31SPEAKER_01: Right.
- 14:31SPEAKER_01: Right.
- 14:52SPEAKER_01: Focus intensely on the quality of earnings.
- 14:55SPEAKER_01: They zero in on the 340B accounting adjustment we discussed,
- 14:58SPEAKER_01: and they enforce realistic limits on competitive market share rather
- 15:02SPEAKER_01: than just extrapolating endless, unconstrained patient demand into the 2030s.
- 15:07SPEAKER_00: So they do agree on the demand, though?
- 15:09SPEAKER_01: Directionally, yes.
- 15:11SPEAKER_01: Everyone broadly agrees demand is huge.
- 15:14SPEAKER_01: The disagreement revealed by the evidence weights is entirely about margins, timing,
- 15:19SPEAKER_01: and what terminal multiple the market will assign to a capital-intensive drugmaker.
- 15:23SPEAKER_00: Well, since there is so much disagreement,
- 15:25SPEAKER_00: we need a timeline to track which models are actually predicting reality.
- 15:29SPEAKER_00: The research gives us a 20-quarter weighted path model.
- 15:32SPEAKER_00: From our 34.80 euro anchor,
- 15:35SPEAKER_00: the modeled cumulative price checkpoints are plus 11.0% by December 2026,
- 15:39SPEAKER_00: plus 14.9% by March 2027, plus 20.8% by June 2027, and plus 25.9% by September 2027.
- 15:51SPEAKER_01: But we have to be incredibly careful here.
- 15:54SPEAKER_00: Right.
- 15:54SPEAKER_00: So if I'm marking my calendar,
- 15:56SPEAKER_00: I need to know that the model's check-ins in December or March aren't necessarily
- 15:59SPEAKER_00: the days Novo is releasing a big study.
- 16:03SPEAKER_01: This raises an important question.
- 16:05SPEAKER_01: You must strictly separate the AI model's arbitrary checkpoints from
- 16:09SPEAKER_01: the company's real-world operational calendar.
- 16:12SPEAKER_01: The model dates are just quarterly check-ins for the algorithm.
- 16:14SPEAKER_01: The actual business catalysts happen on their own schedule.
- 16:18SPEAKER_00: So what are the actual real-world dates?
- 16:20SPEAKER_01: Novo's Q3 results arrive on November 4, 2026.
- 16:24SPEAKER_01: They are awaiting a U.S. FDA decision on Cagracima in Q4, 2026.
- 16:29SPEAKER_01: And remember, a decision is not a guaranteed approval.
- 16:32SPEAKER_01: After that, the Redefine 11 clinical readout window lands in Q1, 2027.
- 16:37SPEAKER_00: And when those clinical readouts drop,
- 16:39SPEAKER_00: we have to look past the headlines,
- 16:40SPEAKER_00: success or failure, and read the deep clinical nuance.
- 16:44SPEAKER_00: If we look back at the recent trials,
- 16:46SPEAKER_00: Redefine 4 and Reimagine 5, they tell totally different stories.
- 16:50SPEAKER_01: They answer entirely different medical questions.
- 16:53SPEAKER_01: So totally different parameters.
- 17:11SPEAKER_01: Yes, the patient population,
- 17:13SPEAKER_01: the dosage, and the primary endpoint dictate the commercial reality.
- 17:17SPEAKER_01: Whenever new primary clinical announcements happen,
- 17:20SPEAKER_01: they immediately supersede the old archived assumptions in the models.
- 17:24SPEAKER_00: Which brings up a great point about navigating the archived research.
- 17:27SPEAKER_00: If the algorithms update their frameworks between the July batch of analysis and
- 17:31SPEAKER_00: the current September batch,
- 17:33SPEAKER_00: how do we confidently track the narrative without getting lost in
- 17:35SPEAKER_00: the technical changes?
- 17:37SPEAKER_01: You have to separate a shift in methodology from an actual shift in the business.
- 17:41SPEAKER_01: The algorithms minor versions differ between the July and September reports,
- 17:45SPEAKER_01: meaning there is no direct like for like comparison.
- 17:49SPEAKER_00: Got it.
- 17:50SPEAKER_01: For instance, the July analysis contained a mention of Novo being debt free.
- 17:55SPEAKER_01: That was a pure analytical error by the model,
- 17:57SPEAKER_01: which was subsequently corrected against the actual balance sheet filings
- 18:00SPEAKER_01: in later runs.
- 18:02SPEAKER_01: Novo did not magically pay off tens of billions in debt overnight.
- 18:05SPEAKER_00: Right.
- 18:06SPEAKER_00: It requires discipline to keep our eyes on the core business problem.
- 18:09SPEAKER_00: It actually reminds me of the last publicly listed stock we covered, SpaceX, in episode 023.
- 18:16SPEAKER_00: It's obviously a totally different industry,
- 18:17SPEAKER_00: building rockets versus formulating pharmaceuticals,
- 18:20SPEAKER_00: but the fundamental tension is identical.
- 18:22SPEAKER_01: The parallel is very strong.
- 18:24SPEAKER_01: Different industries, same fundamental question of funding growth.
- 18:28SPEAKER_01: Having a phenomenal product does not make a company immune to the laws of capital expenditure.
- 18:33SPEAKER_00: Exactly.
- 18:33SPEAKER_01: We covered this from another angle in our Apple EPO16 deep dive.
- 18:38SPEAKER_01: Great business, bad price.
- 18:40SPEAKER_01: A company can be universally admired,
- 18:42SPEAKER_01: but the price you pay for the equity today,
- 18:45SPEAKER_01: weighed against the capital required to maintain its dominance,
- 18:48SPEAKER_01: ultimately dictates your return.
- 18:50SPEAKER_00: Okay, we've mapped out the upside, the intense demand, and the margin compression.
- 18:54SPEAKER_00: Let's look at the breaking point.
- 18:55SPEAKER_00: Okay, we've looked at the upside, but what actually breaks this whole thesis for you?
- 18:59SPEAKER_00: What is the true and validation point?
- 19:01SPEAKER_01: The thesis collapses if a few specific substantive triggers occur.
- 19:06SPEAKER_01: First, if greater patient volumes repeatedly fail to offset the ongoing pressure
- 19:10SPEAKER_01: on realized prices.
- 19:12SPEAKER_00: So if scale doesn't fix the pricing drop.
- 19:14SPEAKER_01: Right.
- 19:15SPEAKER_01: Second, if adjusted margins and cash conversion metrics consistently worsen quarter
- 19:20SPEAKER_01: over quarter, proving the friction is structural rather than temporary.
- 19:24SPEAKER_01: Third, if this massive buildout
- 19:26SPEAKER_01: of new factory capacity ultimately earns poor commercial returns.
- 19:30SPEAKER_00: And obviously if the science fails them.
- 19:32SPEAKER_01: Precisely that.
- 19:34SPEAKER_01: If the next generation's successor treatments disappoint in clinical trials,
- 19:38SPEAKER_01: the future growth premium vanishes.
- 19:41SPEAKER_01: Or if drastic reimbursement changes
- 19:43SPEAKER_01: or adverse patent developments prematurely kill their durable earnings window.
- 19:47SPEAKER_00: It's a lot of moving parts.
- 19:49SPEAKER_01: It is.
- 19:50SPEAKER_01: And crucially,
- 19:51SPEAKER_01: it takes multiple periods of evidence to distinguish between
- 19:54SPEAKER_01: a one-off accounting adjustment,
- 19:56SPEAKER_01: like that 340B reversal, and a true structural decline in daily operations.
- 20:03SPEAKER_00: And we shouldn't lull ourselves into a false sense of security with the dividend, right?
- 20:08SPEAKER_00: Because if the core business degrades structurally,
- 20:10SPEAKER_00: the dividend isn't going to save the valuation.
- 20:13SPEAKER_01: The dividend is a mechanism of capital return, not a safety net.
- 20:17SPEAKER_01: It does not create a guaranteed valuation floor if the fundamental earning power of
- 20:21SPEAKER_01: the company is permanently impaired.
- 20:24SPEAKER_00: So synthesizing everything we've uncovered today,
- 20:27SPEAKER_00: we set out to figure out how Novo Nordisk handles the friction
- 20:31SPEAKER_00: between massive demand and massive expansion costs.
- 20:34SPEAKER_00: The core takeaway is that while the patient demand is undeniable,
- 20:38SPEAKER_00: generating sustainable profits requires the company
- 20:41SPEAKER_00: to successfully defend its margins and Earn high returns
- 20:44SPEAKER_00: on its new manufacturing facilities and actually generate free cash after all
- 20:48SPEAKER_00: the heavy investments are paid for.
- 20:50SPEAKER_01: The exact arithmetic,
- 20:52SPEAKER_01: the valuation scenarios and the companion episodes we referenced all highlight
- 20:57SPEAKER_01: the sheer tension between top line revenue growth and the bottom line reality
- 21:01SPEAKER_01: of funding that growth.
- 21:03SPEAKER_00: It's the movie theater problem.
- 21:04SPEAKER_00: The blockbuster is playing,
- 21:05SPEAKER_00: but we have to see if building the theaters actually leaves any money in
- 21:08SPEAKER_00: the register.
- 21:10SPEAKER_01: You can inspect the dated research and the full 20-quarter path at ipulseai.com.
- 21:15SPEAKER_01: Listen or watch our Volkswagen,
- 21:17SPEAKER_01: NVIDIA, and Apple conversations for three other views of capital and valuation.
- 21:21SPEAKER_01: Subscribe to AI Investment Edge if these discussions are useful.
- 21:24SPEAKER_01: Next is Boston Scientific.
- 21:26SPEAKER_01: How does its medical device growth turn into durable earnings and cash?
- 21:30SPEAKER_00: So as you watch this industry evolve,
- 21:32SPEAKER_00: ask yourself,
- 21:33SPEAKER_00: when you see massive demand for a product,
- 21:35SPEAKER_00: are you looking at the volume of users or the cost of the factories required
- 21:38SPEAKER_00: to serve them?